3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
51
INDUSTRY
17
NIH
6
NETWORK
2
OTHER_GOV
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group N
1
Fanconi Anemia, Complementation Group D1
1
Interventions
pembrolizumab
3
enzalutamide
2
Testosterone
2
Itraconazole
2
Exercise
2
zanubrutinib
1
venetoclax
1
stenoparib
1
relugolix
1
olaparib
1
nilutamide
1
ibrutinib
1
histrelin
1
capivasertib
1
bicalutamide
1
apalutamide
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
acalabrutinib
1
abiraterone
1
Waiting Lists
1
Triptorelin Pamoate
1
Temozolomide
1
Surveys and Questionnaires
1
Radiosurgery
1
Prednisone
1
Pluvicto
1
PM 01183
1
Nutritional Status
1
Nivolumab
1
Methylprednisolone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
FED
×
olaparib
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled